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. Since the release of these new guidelines, additional evidence has emerged that may suggest a rationale for extending statin consideration to an even larger proportion of asymptomatic adults. Some new evidence would support that a treatment threshold even below 7.5% risk of ASCVD in 10 years could be justified. In this review, we discuss new findings since 2013, and propose strategies emanating from the current guidelines to help clinicians and patients make more informed decisions about long-term statin use. This is especially pertinent to lower-risk patients.
MANY EVENTS OCCUR IN "LOW-RISK" PEOPLE
Many ASCVD events occur among people with predicted 10-year risk below 7.5%, raising the potential for additional clinical benefits of a broader application of statins. This issue has been addressed by a number of analyses of population data, and it is clear that large numbers of ASCVD events occur in so-called low-risk people. This is due to the fact that "low-risk" is not the same as "no risk," and very large numbers of low-risk people exist within the general population. 
ACCURACY OF RISK ASSESSMENT TOOLS
Since the release of the ACC/AHA guideline, some debate has focused on the accuracy of the risk estimator, the Pooled Cohort Equation (PCE). Several analyses from cohorts derived from populations with high socioeconomic status, or very healthy or clinical trial populations, reported that the PCE overestimated risk (14, 15) . Other analyses utilizing populations likely to be more representative of the broad U.S. population suggested that the PCE predicted risk accurately (16, 17) . At the same time, some observers commented that all risk models are imperfect, a perspective that is important to consider (18) . The ACC/ AHA Risk Assessment Guidelines (19) , and the JBS guideline (20) Recognizing the inaccuracy of all risk estimation approaches, the ACC/AHA Risk Assessment Guideline advised that risk assessment using the PCE should be only the initial step in making an informed decision about statin treatment. The next step for virtually all patients, following either the ACC/AHA guideline (2), the JBS guideline (20) , or the VA/DoD guideline (1), is the clinician-patient discussion. Two reasons for the discussion are apparent: 1) patients differ in their preferences and comfort levels with regard to preventive strategies and long-term medication use; and 2) risk assessment is inherently better for populations than it is for specific people. This is also true for benefit assessment. Explicit risk and benefit assessment are an improvement over clinical intuition alone, but they remain essentially educated guesses as to who precisely will benefit (21) . As the ACC/AHA cholesterol guideline noted, RCT evidence supports a net absolute benefit of using moderate-to-intensive statin therapy at a baseline 10-year ASCVD risk $7.5%; consequently, statins can be strongly recommended in this population group. Available RCT evidence also indicates that when baseline ASCVD risk is 5.0% to <7.5%, at the population level, there is still net absolute benefit with moderate-intensity statin therapy, on average. However, the tradeoffs between the ASCVD risk-reduction benefit and adverse effects are marginal in this lower-risk group. In all risk groups, mindful of the limitations of risk estimation, a clinician-patient discussion is critically important (22) . In preventive cardiology, one never knows for certain if the patient is the 1 in 5 (or 1 in 25 or 1 in 50) who will eventually develop a CVD event. The decision, therefore, always represents a tradeoff of benefit and risk, which relies on the best estimates of both of these factors, and a respectful inclusion of patient preferences. This is the essential idea of personalized medicine, a concept that has informed medical practice for decades, if not centuries. What is new is the importance of recognizing that all risk models are somewhat flawed in terms of accuracy of prediction. Their purpose is to provide a general estimate of risk that appropriately begins the decision-making process or risk discussion with the patient (21). <2 mg/l, homocysteine <10 mmol/l, N-terminal pro-Btype natriuretic peptide <100 pg/ml, no microalbuminuria, no family history of coronary heart disease (CHD) (any or premature), absence of metabolic syndrome, and healthy lifestyle were compared for the endpoints of CHD and all CVD events over 10 years' follow-up. They described these normal or low test results as "negative risk markers." The strongest negative risk marker was a CAC score of 0 for both all CHD and total CVD outcomes, followed by carotid intima-media thickness <25th percentile, perhaps not surprisingly, as they are both markers of atherosclerosis burden. An hsCRP <2 mg/l and normal ABI were not useful for modifying assessment of low risk. 
NEW EVIDENCE ON THE ROLE OF ADDITIONAL MARKERS OF RISK IN LOWER-AND INTERMEDIATE-RISK PATIENTS

NEW EVIDENCE ON EFFECTIVENESS OF STATINS ON THE BASIS OF RISK ALONE
In considering whether to lower the risk threshold for statin use from a 10-year risk threshold of 7.5%, an important consideration is whether statins are effective in lower-risk people and by how much. 
